The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Talya Wolak, Soroka University Medical Center
ClinicalTrials.gov Identifier:
NCT01071642
First received: February 18, 2010
Last updated: October 30, 2011
Last verified: October 2011
  Purpose

The aim of the current study is to evaluate prospectively whether concomitant administration of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.


Condition Intervention
Blood Pressure
Drug: stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure
Drug: ACE/ARB stopped 24 hours before procedure and start immediately after

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Further study details as provided by Soroka University Medical Center:

Primary Outcome Measures:
  • Change in eGFR from baseline to 48 hours following the exposure to the contrast. [ Time Frame: 48 hours after exposure to the contrast ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • 1. Rate of eGFR decrease>25% from the baseline, 2. Length of hospitalization, [ Time Frame: 48-72 hours after exposure to contrast ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: March 2010
Study Completion Date: November 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: continue ace-i and arb's versus dicontinue
Active Comparator: group b Drug: stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure
ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
Active Comparator: group c Drug: ACE/ARB stopped 24 hours before procedure and start immediately after
ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Age>18 years
  • 2. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file)
  • 3. Subjects planned to undergo non-emergent coronary angiography.
  • 4. Signed informed consent

Exclusion Criteria:

  • 1. eGFR<30 ml/min at baseline
  • 2. Chronic utilization of NSAIDS and Cox-2 selective inhibitors
  • 3. Chronic treatment with mineralocorticosteroid receptor blocker
  • 4. Systolic blood pressure<90 mmHg
  • 5. Planned staged (repeated) procedure within 48 hours
  • 6. Administration of contrast within 14 days prior to the enrollment
  • 7. contraindication to stop ACE-I or ARB'S
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01071642

Locations
Israel
Talya Wolak
Bear Sheva, Israel, 8410
Sponsors and Collaborators
Soroka University Medical Center
  More Information

No publications provided

Responsible Party: Talya Wolak, senior doctor internal medicine department, Soroka University Medical Center
ClinicalTrials.gov Identifier: NCT01071642     History of Changes
Other Study ID Numbers: sor495209ctil
Study First Received: February 18, 2010
Last Updated: October 30, 2011
Health Authority: Israel: The Israel National Institute for Health Policy Research and Health Services Research

Keywords provided by Soroka University Medical Center:
Change in eGFR from baseline to 72 hours following the exposure to the contrast.
Rate of eGFR decrease>25% from the baseline
Length of hospitalization.
Requirement of unplanned therapy for elevated blood pressure

Additional relevant MeSH terms:
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors
Angiotensin Receptor Antagonists
Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 31, 2014